EP4200301C0 - Phospholipidverbindungen und verwendungen davon - Google Patents

Phospholipidverbindungen und verwendungen davon

Info

Publication number
EP4200301C0
EP4200301C0 EP21772895.5A EP21772895A EP4200301C0 EP 4200301 C0 EP4200301 C0 EP 4200301C0 EP 21772895 A EP21772895 A EP 21772895A EP 4200301 C0 EP4200301 C0 EP 4200301C0
Authority
EP
European Patent Office
Prior art keywords
phospholipid compounds
phospholipid
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP21772895.5A
Other languages
English (en)
French (fr)
Other versions
EP4200301B1 (de
EP4200301A1 (de
Inventor
Scott E Lazerwith
Jonathan William Medley
Philip A Morganelli
Devan Naduthambi
Thomas P Stratton
Peiyuan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to EP25159918.9A priority Critical patent/EP4537828A3/de
Publication of EP4200301A1 publication Critical patent/EP4200301A1/de
Application granted granted Critical
Publication of EP4200301C0 publication Critical patent/EP4200301C0/de
Publication of EP4200301B1 publication Critical patent/EP4200301B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21772895.5A 2020-08-24 2021-08-23 Phospholipidverbindungen und verwendungen davon Active EP4200301B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP25159918.9A EP4537828A3 (de) 2020-08-24 2021-08-23 Phospholipidverbindungen und verwendungen davon

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063069449P 2020-08-24 2020-08-24
US202063092386P 2020-10-15 2020-10-15
US202163151509P 2021-02-19 2021-02-19
PCT/US2021/047145 WO2022046631A1 (en) 2020-08-24 2021-08-23 Phospholipid compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP25159918.9A Division EP4537828A3 (de) 2020-08-24 2021-08-23 Phospholipidverbindungen und verwendungen davon

Publications (3)

Publication Number Publication Date
EP4200301A1 EP4200301A1 (de) 2023-06-28
EP4200301C0 true EP4200301C0 (de) 2025-02-26
EP4200301B1 EP4200301B1 (de) 2025-02-26

Family

ID=77802251

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21772895.5A Active EP4200301B1 (de) 2020-08-24 2021-08-23 Phospholipidverbindungen und verwendungen davon
EP25159918.9A Pending EP4537828A3 (de) 2020-08-24 2021-08-23 Phospholipidverbindungen und verwendungen davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP25159918.9A Pending EP4537828A3 (de) 2020-08-24 2021-08-23 Phospholipidverbindungen und verwendungen davon

Country Status (19)

Country Link
US (3) US11773122B2 (de)
EP (2) EP4200301B1 (de)
JP (2) JP7559223B2 (de)
KR (1) KR20230057419A (de)
CN (1) CN116323630B (de)
AU (2) AU2021330835B2 (de)
BR (1) BR112023002951A2 (de)
CA (1) CA3188373A1 (de)
CL (1) CL2023000524A1 (de)
CO (1) CO2023001953A2 (de)
CR (1) CR20230100A (de)
DO (1) DOP2023000037A (de)
ES (1) ES3015457T3 (de)
IL (1) IL300412A (de)
MX (1) MX2023002233A (de)
PE (1) PE20231847A1 (de)
PL (1) PL4200301T3 (de)
TW (2) TW202337471A (de)
WO (1) WO2022046631A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021312946A1 (en) 2020-07-24 2023-03-09 The Regents Of The University Of California Antiviral prodrugs, pharmaceutical formulations, and methods
MX2023002233A (es) 2020-08-24 2023-03-15 Gilead Sciences Inc Compuestos fosfolipidos y usos de estos.
TWI811812B (zh) * 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
CA3247143A1 (en) * 2022-01-26 2023-08-03 The Regents Of The University Of California Antiviral prodrugs, intermediate and long-acting formulations, and methods
CN115251042B (zh) * 2022-09-08 2023-06-02 安徽科技学院 一种家禽精液稀释缓冲液及其制备和家禽精液冷存方法
CN118165034A (zh) * 2022-12-09 2024-06-11 深圳市塔吉瑞生物医药有限公司 核苷酸类化合物及其组合物及用途
CN117024479A (zh) * 2023-08-04 2023-11-10 杭州居维叶生物医药有限公司 一种聚乙二醇化磷酸前药及其制备与应用
CN119954834B (zh) * 2025-02-07 2025-08-05 湖南尚成生物科技有限公司 一种化合物或其药学上可接受的盐、水合物、溶剂化物或前药及其用途

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0262876B1 (de) 1986-09-27 1992-04-29 Toyo Jozo Kabushiki Kaisha Nukleosid-Phospholipid-Konjugat
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
AU785355B2 (en) 1999-12-03 2007-02-01 Regents Of The University Of California At San Diego, The Phosphonate compounds
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
US6596700B2 (en) 2000-05-26 2003-07-22 Idenix Pharmaceuticals Inc. Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
BRPI0411900B8 (pt) 2003-06-26 2021-05-25 Biotron Ltd compostos e composições farmacêuticas compreendendo os mesmos
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
ES2401285T3 (es) 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
PT2826770T (pt) 2005-06-24 2018-12-18 Biotron Ltd Compostos acilguanidinas com atividade antiviral
WO2009018609A1 (en) 2007-08-03 2009-02-12 Biotrom Limited Hepatitis c antiviral compositions and methods
HRP20130048T1 (hr) 2008-04-23 2013-02-28 Gilead Sciences, Inc. Karba-nukleozidni analozi za antivirusnu terapiju
EP2313102A2 (de) 2008-07-03 2011-04-27 Biota Scientific Management Bicyclische nucleoside und nucleotide als therapeutische mittel
EP2342616A2 (de) 2008-09-23 2011-07-13 Alnylam Pharmaceuticals Inc. Chemische modifikationen von monomeren und oligonukleotiden mit cycloaddition
JP5752599B2 (ja) 2008-11-06 2015-07-22 ヴァスキュラー バイオジェニックス リミテッド 酸化脂質化合物およびその使用
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011035250A1 (en) 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
AU2010295373B2 (en) 2009-09-21 2016-09-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011059021A1 (ja) 2009-11-11 2011-05-19 大日本住友製薬株式会社 ８－アザビシクロ［３．２．１］オクタン－８－カルボキサミド誘導体
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
MX2015002954A (es) 2012-09-10 2015-06-05 Hoffmann La Roche Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b.
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
SMT201800538T1 (it) 2013-03-15 2019-01-11 Univ California Diesteri di fosfonato nucleosidico aciclico
HK1224229A1 (zh) 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷，核苷酸及其类似物
PL3043865T3 (pl) 2013-09-11 2021-07-05 Institut National De La Santé Et De La Recherche Médicale (Inserm) SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B
JP6562908B2 (ja) 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
JP2017504633A (ja) 2014-01-30 2017-02-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染の治療及び予防のための新規なジヒドロキノリジノン
ES2714110T3 (es) 2014-03-07 2019-05-27 Hoffmann La Roche Heteroarildihidropirimidinas 6-fusionadas novedosas para el tratamiento y profilaxis de la infección por el virus de la hepatitis B
CA2948080A1 (en) 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
CN106573898B (zh) 2014-08-14 2018-11-09 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的哒嗪酮和三嗪酮
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
AR103222A1 (es) 2014-12-23 2017-04-26 Hoffmann La Roche Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CN107108610B (zh) 2014-12-30 2019-06-04 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016120186A1 (en) 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
EP3256471B1 (de) 2015-02-11 2018-12-12 F. Hoffmann-La Roche AG Neuartige 2-oxo-6,7-dihydrobenzo[a]chinolizin-3-carboxylsäure-derivate zur behandlung und prophylaxe von hepatitis-b-virusinfektion
WO2017024310A1 (en) 2015-08-06 2017-02-09 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
HRP20220355T1 (hr) 2015-09-16 2022-05-13 Gilead Sciences, Inc. Postupci za liječenje infekcija coronaviridae
US10874683B2 (en) 2016-03-10 2020-12-29 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11963972B2 (en) 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus
AU2018218179B2 (en) 2017-02-08 2023-05-04 Biotron Limited Methods of treating influenza
CN116036112A (zh) 2017-03-14 2023-05-02 吉利德科学公司 治疗猫冠状病毒感染的方法
US11306111B2 (en) 2017-07-31 2022-04-19 January Therapeutics, Inc. Organophosphate derivatives
CA3075950A1 (en) 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA3087192A1 (en) 2017-12-27 2019-07-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
CN110054616B (zh) * 2018-01-19 2021-11-23 南京圣和药业股份有限公司 三嗪类idh抑制剂的制备方法
WO2019169323A1 (en) 2018-03-02 2019-09-06 January Therapeutics, Inc. Nanoparticle compositions
JP7678802B2 (ja) 2019-11-04 2025-05-16 アレクトル エルエルシー Ｓｉｇｌｅｃ－９ＥＣＤ融合分子及びその使用方法
TWI791193B (zh) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
CN113292565B (zh) 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
CN111233929B (zh) 2020-02-28 2023-02-28 成都阿奇生物医药科技有限公司 一种核苷类似物的氘代物及其制备方法和用途
CN111393243B (zh) 2020-04-22 2022-12-13 深圳市宝安区新材料研究院 一种磷手性核苷类药物的合成方法及该方法得到的药物
AU2021312946A1 (en) 2020-07-24 2023-03-09 The Regents Of The University Of California Antiviral prodrugs, pharmaceutical formulations, and methods
MX2023002233A (es) 2020-08-24 2023-03-15 Gilead Sciences Inc Compuestos fosfolipidos y usos de estos.
CN112010916B (zh) 2020-09-09 2022-12-27 广东东阳光药业有限公司 核苷化合物的氨基磷酸酯衍生物及其用途
CA3196712A1 (en) 2020-09-23 2022-03-31 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
WO2022081976A1 (en) 2020-10-16 2022-04-21 Dana-Farber Cancer Institute, Inc. Piperidinyl small molecule degraders of helios and methods of use
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN112645982B (zh) 2020-12-22 2023-04-07 苏州正济药业有限公司 一种瑞德西韦关键中间体的制备和纯化方法
EP4294798A1 (de) 2021-02-19 2023-12-27 Kalvista Pharmaceuticals Limited Faktor xiia-hemmer
US11795159B2 (en) 2021-05-26 2023-10-24 Purdue Research Foundation Compounds for the treatment of SARS
US11834408B2 (en) 2021-05-28 2023-12-05 Purdue Research Foundation Compounds for the treatment of SARS
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
CN115475171B (zh) 2021-06-16 2025-03-07 中国医学科学院医药生物技术研究所 一种具有抗冠状病毒活性的化合物及其应用
WO2022270478A1 (ja) 2021-06-21 2022-12-29 国立大学法人北海道大学 抗ウイルス剤
CN115504940A (zh) 2021-06-23 2022-12-23 中国科学院上海药物研究所 一种酰胺类化合物、其制备方法和制药用途
WO2022268111A1 (zh) 2021-06-25 2022-12-29 前沿生物药业(南京)股份有限公司 抗病毒药物组合物及其制备方法和应用
KR102766444B1 (ko) 2021-06-28 2025-02-11 재단법인 대구경북첨단의료산업진흥재단 트리아지노인돌 유도체를 유효성분으로 하는 항바이러스제
WO2023279031A1 (en) 2021-06-29 2023-01-05 The Regents Of The University Of California Methods and compositions for treatment of covid-19
WO2023272571A1 (zh) 2021-06-30 2023-01-05 中国人民解放军军事科学院军事医学研究院 2,3-环氧丁二酰衍生物的医药用途
US20250057802A1 (en) 2021-07-08 2025-02-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Broad-spectrum antiviral drugs
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
WO2023283831A1 (zh) 2021-07-14 2023-01-19 上海药明康德新药开发有限公司 病毒主蛋白酶抑制剂及其制备方法和用途
EP4159211A4 (de) 2021-07-15 2024-10-30 National Center for Global Health and Medicine Verbindung mit physiologischer aktivität wie antiviraler aktivität
EP4119145A1 (de) 2021-07-15 2023-01-18 Dompe' Farmaceutici S.P.A. Verbindungen zur behandlung von covid-19
WO2023004291A1 (en) 2021-07-19 2023-01-26 Baylor College Of Medicine Coronavirus main protease inhibitors and methods using same
TW202321210A (zh) 2021-07-22 2023-06-01 瑞士商諾華公司 用於治療冠狀病毒相關疾病之化合物及組成物
WO2023003610A1 (en) 2021-07-23 2023-01-26 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2023009187A1 (en) 2021-07-29 2023-02-02 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
KR102806503B1 (ko) 2021-07-29 2025-05-16 가톨릭대학교 산학협력단 렘데시비르와 면역조절제 병용투여법을 통한 자가면역류마티스 질환 치료용 조성물
JPWO2023008530A1 (de) 2021-07-30 2023-02-02
JP7810788B2 (ja) 2021-08-02 2026-02-03 北京華益健康薬物研究中心 コロナウイルス感染症の治療又は予防のための３ｃｌプロテア－ゼ小分子阻害剤及びその用途
EP4130001A1 (de) 2021-08-03 2023-02-08 Studiengesellschaft Kohle mbH Verfahren zur direkten katalytischen glycosylierung von arenen
JP2024530920A (ja) 2021-08-03 2024-08-27 コクリスタル ファーマ，インコーポレイテッド コロナウイルスに対する阻害剤
WO2023012329A1 (en) 2021-08-06 2023-02-09 Intervet International B.V. Method of treating veterinary viral diseases
CN115703796A (zh) 2021-08-09 2023-02-17 苏州恩泰新材料科技有限公司 一种瑞德西韦重要中间体制备方法
JP2023026155A (ja) 2021-08-13 2023-02-24 国立研究開発法人理化学研究所 感染症治療薬
WO2023039330A2 (en) 2021-08-17 2023-03-16 Southwest Research Institute Antiviral drugs targeting the n-terminal domain (ntd) of the coronavirus spike receptor binding domain (rbd)
JP2024531898A (ja) 2021-08-17 2024-09-03 サウスウエスト リサーチ インスティテュート コロナウイルスに対する阻害剤
EP4387625A1 (de) 2021-08-17 2024-06-26 Farahani, Ensieh Verbindungen zur behandlung von virusinfektionen durch neurotropes virus
EP4387629A1 (de) 2021-08-18 2024-06-26 Katholieke Universiteit Leuven KU Leuven Research & Development 6-substituierte und 6,7-disubstituierte 7-deazapurin-ribonukleosidanaloga
JP7719954B2 (ja) * 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
WO2023023631A1 (en) 2021-08-18 2023-02-23 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
CN113648293B (zh) 2021-08-19 2022-07-05 山东达因海洋生物制药股份有限公司 对苯醌和/或对苯醌衍生物在制备抗新型冠状病毒药物中的应用
US20240391876A1 (en) 2021-08-19 2024-11-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Quinacrine and derivatives thereof for treatment of viral infections
WO2023022216A1 (ja) 2021-08-20 2023-02-23 塩野義製薬株式会社 ウイルス増殖抑制作用を有するヌクレオシド誘導体及びそれらのプロドラッグ
JPWO2023022231A1 (de) 2021-08-20 2023-02-23
CN115716833A (zh) 2021-08-26 2023-02-28 苏州旺山旺水生物医药有限公司 一种抗病毒核苷类似物的制备方法
US12234202B2 (en) 2021-08-27 2025-02-25 Ut-Battelle, Llc Covalent inhibitors of coronavirus papain-like protease
CN117886870A (zh) 2021-08-27 2024-04-16 南京知和医药科技有限公司 一种新型的胞苷衍生物及其药物组合物和用途
WO2023034854A1 (en) 2021-08-31 2023-03-09 Pardes Biosciences, Inc. Crystalline inhibitors of cysteine proteases and methods of use thereof
CN115721661A (zh) 2021-09-01 2023-03-03 常晓宇 嘌呤核苷类药物预防或治疗冠状病毒感染性疾病的用途
CN115745960B (zh) 2021-09-02 2024-08-30 中国科学院上海药物研究所 一类含喹啉酮酰胺的化合物及其制备方法、药物组合物和用途
CN115737665A (zh) 2021-09-02 2023-03-07 广州谷森制药有限公司 胞苷衍生物和与其相关的抗病毒用途
JP2024178473A (ja) 2021-09-03 2024-12-25 塩野義製薬株式会社 ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
JP2024534270A (ja) 2021-09-07 2024-09-18 上海齊魯制藥研究中心有限公司 ３ＣＬｐｒｏプロテアーゼ阻害剤
JP7735531B2 (ja) 2021-09-09 2025-09-08 広東衆生睿創生物科技有限公司 ケトアミド誘導体およびその用途
EP4148042A1 (de) 2021-09-10 2023-03-15 Centre National de la Recherche Scientifique Phenoxy-acetyl-thioureido-benzolsulfonamid-derivate und ihre verwendungen
WO2023043830A1 (en) 2021-09-15 2023-03-23 Clear Creek Bio, Inc. Combination therapies to treat viral infections
US20240400560A1 (en) 2021-09-17 2024-12-05 Shionogi & Co., Ltd. Bicyclic heterocyclic derivative having viral growth inhibitory activity and pharmaceutical composition containing same
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2023044462A1 (en) 2021-09-17 2023-03-23 Pardes Biosciences, Inc. Cysteine protease inhibitor formulations and method of use thereof
CN115819391A (zh) 2021-09-17 2023-03-21 中国科学院上海药物研究所 一类黄芩素衍生物、其制备方法和用途
CN115554303B (zh) 2021-09-18 2024-07-09 上海科技大学 一种三环类化合物、其制备方法及其应用
WO2023044171A1 (en) 2021-09-20 2023-03-23 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2023048151A1 (ja) 2021-09-22 2023-03-30 塩野義製薬株式会社 ウイルス増殖阻害活性を有する環状ペプチド
EP4405357A1 (de) 2021-09-23 2024-07-31 Katholieke Universiteit Leuven KU Leuven Research & Development Ribonukleosidanaloga gegen -sars-cov-2
WO2023049643A1 (en) 2021-09-23 2023-03-30 City Of Hope Inhibitors of sars-cov-2
US12186309B2 (en) 2021-09-27 2025-01-07 The Governors Of The University Of Alberta RNA virus inhibitor compounds and uses thereof
TW202320793A (zh) 2021-09-28 2023-06-01 日商塩野義製藥股份有限公司 含有三嗪衍生物之醫藥組合物
TW202330513A (zh) 2021-09-28 2023-08-01 加拿大商愛彼特生物製藥公司 )抑制劑及其使用方法
EP4159721A1 (de) 2021-09-30 2023-04-05 Qubit Pharmaceuticals Kondensierte piperidinederivate als inhibitoren der 3-chymotrypsin-ähnlichen protease von coronaviren
WO2023054759A1 (ko) 2021-09-30 2023-04-06 한국화학연구원 2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물
CN116113631B (zh) 2021-09-30 2023-09-26 中国科学院上海药物研究所 一类氰基化合物、其制备方法及用途
GB202114032D0 (en) 2021-09-30 2021-11-17 Univ Strathclyde Antivirals
CN115894587B (zh) 2021-09-30 2026-05-05 南京赛弗斯医药科技有限公司 一种核苷衍生物的制备及其在抗病毒药物领域中的用途
WO2023059792A1 (en) 2021-10-06 2023-04-13 C4 Thrapeutics, Inc. Coronavirus non-structural protein 3 degrading compounds
KR20230049329A (ko) 2021-10-06 2023-04-13 (주)스파크바이오파마 피리미도디아제핀계 화합물 및 코로나바이러스 감염의 치료 또는 예방을 위한 이의 용도
CN115947758A (zh) 2021-10-07 2023-04-11 南京知和医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
WO2023063884A2 (en) 2021-10-12 2023-04-20 Nanyang Technological University Generation of chiral sulfinate esters
JP2024540877A (ja) 2021-10-13 2024-11-06 クリア クリーク バイオ， インコーポレイテッド コロナウイルスを処置するための化合物および方法
CN115710297A (zh) 2021-10-20 2023-02-24 知和(山东)大药厂有限公司 一种新型核苷酸衍生物类及其药物组合物和用途
EP4417608A1 (de) 2021-11-04 2024-08-21 Shenzhen Antiv Pharma Co., Ltd. Kristallform einer isobuttersäurenukleosidverbindung und herstellungsverfahren
CN115806570B (zh) 2021-11-15 2023-09-12 南京知和医药科技有限公司 一种拟肽衍生物及其药物组合物和用途
EP4289432A4 (de) 2021-11-24 2025-01-15 Shionogi & Co., Ltd Triazinderivate enthaltende zubereitung zur oralen verabreichung
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN115518058A (zh) 2021-12-29 2022-12-27 河北医科大学 N-环烷基取代的芳甲胺类化合物在制备抗病毒药物中的用途及结构和制备方法
US11760722B2 (en) 2022-01-18 2023-09-19 Ascletis Bioscience Co., Ltd. Inhibitors of cysteine proteases and methods of use thereof
WO2023054732A2 (ja) 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
CN116925040B (zh) 2022-03-31 2025-07-29 陕西盘龙药业集团股份有限公司 一种靶向冠状病毒3CL蛋白酶的PROTACs及其制备方法与应用
CN115504964A (zh) 2022-04-12 2022-12-23 海创药业股份有限公司 氘代杂环酮类化合物及其用途
CN115650959B (zh) 2022-05-20 2023-10-20 南京济群医药科技股份有限公司 化合物的制备方法或纯化方法
CN115636817B (zh) 2022-06-20 2023-11-24 山东大学 含三唑环的靛红类衍生物及其制备方法与应用
CN116496266A (zh) 2022-07-08 2023-07-28 歌礼生物科技（杭州）有限公司 三嗪衍生物
CN115572298B (zh) 2022-07-22 2024-11-08 苏州旺山旺水生物医药股份有限公司 一种核苷类似物及其盐的晶型、制备方法和应用
CN115466225B (zh) 2022-08-16 2025-03-07 中国科学院上海药物研究所 一种酰胺类化合物及其制备方法、药物组合物和用途
CN115521208B (zh) 2022-09-21 2023-09-01 天津科技大学 新型冠状病毒3cl蛋白酶抑制剂和应用
CN115521316B (zh) 2022-09-23 2024-07-26 深圳安泰维生物医药有限公司 一种核苷类化合物或其中间体的制备方法和核苷类化合物的中间体
CN115521337A (zh) 2022-09-26 2022-12-27 南京康立瑞生物科技有限公司 一种瑞德西韦中间体的合成方法
CN115894498A (zh) 2022-10-01 2023-04-04 海化生命(厦门)科技有限公司 一种潜在抗病毒药物中间体bl及其合成方法
US11655255B2 (en) 2022-10-17 2023-05-23 Sph No.1 Biochemical & Pharmaceutical Co., Ltd. Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein
CN115894504A (zh) 2022-10-21 2023-04-04 深圳信立泰药业股份有限公司 一种冠状病毒3cl蛋白酶抑制剂及其用途
CN115651022A (zh) 2022-10-27 2023-01-31 南京康立瑞生物科技有限公司 一种高纯度瑞德西韦中间体的合成方法
CN115887471B (zh) 2022-11-01 2024-02-13 南开大学 瑞德西韦在制备治疗皮肤纤维化疾病药物中的应用
CN115894443B (zh) 2022-11-17 2024-03-29 上海市重大传染病和生物安全研究院 一种化合物艾奎斯韦及其应用
CN116514783A (zh) 2022-11-21 2023-08-01 歌礼生物科技（杭州）有限公司 三嗪衍生物
CN115819423B (zh) 2022-11-29 2024-11-22 武汉大学 一种瑞德西韦或其中间体的protac化合物及其制备方法与抗ev71的应用
CN115850338A (zh) 2022-12-12 2023-03-28 西安交通大学 一种含有双吖丙啶核苷类化合物及制备方法和应用
CN115947759A (zh) 2022-12-13 2023-04-11 安徽大学 一种治疗新冠药物瑞德西韦的制备方法
CN115785080B (zh) 2022-12-16 2024-10-11 陕西盘龙药业集团股份有限公司 一种尿嘧啶母核类化合物及其制备方法和应用

Also Published As

Publication number Publication date
JP2024109964A (ja) 2024-08-14
EP4537828A3 (de) 2025-05-28
MX2023002233A (es) 2023-03-15
IL300412A (en) 2023-04-01
CO2023001953A2 (es) 2023-03-17
PL4200301T3 (pl) 2025-06-09
AU2024201573B2 (en) 2026-05-07
CA3188373A1 (en) 2022-03-03
CL2023000524A1 (es) 2023-09-29
BR112023002951A2 (pt) 2023-03-21
PE20231847A1 (es) 2023-11-21
AU2024201573A1 (en) 2024-04-04
US11773122B2 (en) 2023-10-03
CN116323630B (zh) 2026-02-06
US12030904B2 (en) 2024-07-09
ES3015457T3 (en) 2025-05-05
JP2023538442A (ja) 2023-09-07
AU2021330835B2 (en) 2023-12-14
US20230250117A1 (en) 2023-08-10
TW202337471A (zh) 2023-10-01
CN116323630A (zh) 2023-06-23
DOP2023000037A (es) 2023-07-09
CR20230100A (es) 2023-04-28
US12473314B2 (en) 2025-11-18
TW202222323A (zh) 2022-06-16
EP4537828A2 (de) 2025-04-16
US20220081455A1 (en) 2022-03-17
EP4200301B1 (de) 2025-02-26
EP4200301A1 (de) 2023-06-28
US20240025932A1 (en) 2024-01-25
WO2022046631A1 (en) 2022-03-03
KR20230057419A (ko) 2023-04-28
JP7559223B2 (ja) 2024-10-01
TWI807399B (zh) 2023-07-01
AU2021330835A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
EP4351533A4 (de) Apoe- und apob-modifizierte lipidnanopartikelzusammensetzungen und verwendungen davon
EP4081308A4 (de) Smarca-degrader und verwendungen davon
EP4262883C0 (de) Peg-lipide und lipidnanopartikel
EP4204391A4 (de) Lipidverbindungen und lipidnanopartikelzusammensetzungen
PT4196479T (pt) Compostos de piridotriazinas substituídos e suas utilizações
EP4329739A4 (de) Lipidnanomaterialien und verwendungen davon
PL4200301T3 (pl) Związki fosfolipidowe i ich zastosowania
DE112022004033A5 (de) Leuchte und Leuchtenanordnung
EP4342532C0 (de) Antiplättchenarzneimittel und verwendungen davon
EP4324833A4 (de) Alkynylphenylbenzamidverbindung und verwendung davon
EP4126844A4 (de) Amidverbindungen und verwendungen davon
EP4155299A4 (de) Fluorpyrimidinverbindung und fluorpyrimidinonverbindung
EP4504190A4 (de) Oxadiazol-hdac6-inhibitoren und verwendungen davon
EP4415713A4 (de) Bupivacain-multivesikuläre liposomformulierungen und verwendungen davon
EP4285772A4 (de) Einlegesohle und deren kombination
EP4350263A4 (de) Waschtrockner und waschtrockner
EP4198040C0 (de) Pt-dpephos-iod-komplex und pt-dpephos-brom-komplex
EP4244205A4 (de) Ire1alpha-inhibitoren und verwendungen davon
EP4444274A4 (de) Zusammensetzungen mit modifizierten phospholipiden und verwendungen davon
EP4329806A4 (de) Anti-siglec-zusammensetzungen und verwendungen davon
EP4321524C0 (de) Lipid und zusammensetzung
EP4197995C0 (de) Pt-xanthen-iod-komplex und pt-xanthen-brom-komplex
EP4265614A4 (de) Verbindung und zusammensetzung
EP4225366A4 (de) Imdq-peg-chol-adjuvans und verwendungen davon
EP4119545C0 (de) Pyrazolcarboxylatverbindung und verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230814

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096311

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240326

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240916

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602021026831

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20250301

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250310

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 46320

Country of ref document: SK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250602

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250226

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250610

Year of fee payment: 5

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 5

Effective date: 20250709

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20250400930

Country of ref document: GR

Effective date: 20250613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250226

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250909

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20250716

Year of fee payment: 5

Ref country code: NO

Payment date: 20250808

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250808

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250703

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250901

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20250730

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20250714

Year of fee payment: 5

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20251127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250226

U1N Appointed representative for the unitary patent procedure changed after the registration of the unitary effect

Representative=s name: MARKS & CLERK LLP; GB